Micro-environment Involvement in Muscle Alteration Induced

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

27 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-01

Study Completion Date

2020-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent airway obstruction and inflammatory response of the lungs and bronchi. Episodes of exacerbations contribute to increase the severity and prognosis of the disease. Muscle dysfunction (loss of strengh and muscle mass) is one of comorbidities affecting 30% to 60% of patients and playing a key role in their prognosis. During exacerbation, some studies have suggested an association between muscle dysfunction and modifications of inflammatory circulating factors such as CRP, TNF-alpha, IL- 6, IL8, but no exhaustive study has identified precisely one (or more) biomarker(s) that can induce this muscle wasting during the exacerbation of COPD. Our hypothesis is that the serum of exacerbated COPD patients represents a deleterious microenvironment for the muscle cells which would amplify the mechanisms of atrophy linked to hospitalization. Our team has already developed a cell culture model to study the effects of the plasma microenvironment on atrophy of cultured myotubes. The investigators have shown that the serum of COPD patients can induce muscle atrophy.

The objectives of this study are : 1/ to evaluate the effects of circulating pro-inflammatory factors on atrophy and the myogenic capacities of muscle cells; and 2/ to identify one (or more) circulating biomarker (s) that may be responsible for the muscle damage induced by the microenvironment of hospitalized patients for exacerbation of COPD. First, myotubes and myoblasts of healthy subjects will be cultivated with 9 exacerbation copd patient serum or 9 copd patient serum or 9 healthy subject serum. Myotube diameters, atrophy, inflammatory and oxidative stress markers and alteration of the myogenic capacity of satellite cells will be compared between three groups. Second, the differential expression of circulating proinflammatory molecules will be compared in the serum of the three groups. Identifying circulating factors associated with muscle weakness is a necessary step to better understand the mechanisms and consider a personalized therapeutic approach that can improve the functional and clinical prognosis of disease.

.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD)

NCT00864994

Chronic Obstructive Pulmonary Disease

UNKNOWN

Protocol Chronic Obstructive Pulmonary Disease

NCT00404430

Chronic Obstructive Pulmonary Disease Acute Respiratory Failure

COMPLETED

Biological Determinants of Sputum Rheology in Chronic Airway Diseases

NCT04081740

Asthma COPD Bronchiectasis

COMPLETED

HDAC Activity in Peripheral Skeletal Muscle in COPD

NCT00180752

COPD

COMPLETED

Nutritional Status in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT03709498

Pulmonary Disease, Chronic Obstructive

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease Exacerbations Skeletal Muscle Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy subject

No interventions assigned to this group

Stable COPD patients

No interventions assigned to this group

Exacerbation COPD patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitalization for COPD exacerbation 2/ for COPD patients
* COPD patients GOLD II à IV
* Not having followed respiratory réhabilitation stay for at least one year 3/ for Healthy subjects
* healthy and sedentary (Voorips score \<9)

Exclusion Criteria

1. for COPD patients hospitalized for exacerbation:

* concomitant acute cardiac évent
* trachéal intubation with mechanical ventilation
* chronic respiratory disease other than COPD
* locomotor, neurologic or psychiatric comorbidities
2. for COPD patients

* Exacerbation with récent hospitalization (\<4 weeks)
* Neurologic comorbidity
3. for Healthy subjects - long term drug treatment with proven central effects

Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes